Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Novo Nordisk Board Built the Weight-Loss Drug Empire
Transcript
- Lucas: Luna, as of mid-2026, Novo Nordisk is the most valuable company in Europe — worth more than LVMH, more than Nestlé, more than ASML. And that's almost entirely because of two drugs: Ozempic and Wegovy. Luna: Right, semaglutide. The molecule that changed obesity treatment. But the question I've always had is — how did the board actually steer that? Because this wasn't an overnight success. Semaglutide was in development for over a decade. Lucas: Exactly. And that's the fascinating governance story. The board of Novo Nordisk made a series of deliberate, patient bets that most companies wouldn't have made. To understand why, you have to understand the ownership structure. Luna: The Novo Nordisk Foundation. It controls about 77 percent of the voting rights. So the board isn't facing pressure from activist hedge funds every quarter. Lucas: Precisely. The foundation's mandate is to generate returns that fund scientific research. That gives the board a time horizon measured in decades, not quarters. And that's exactly what they needed when they decided to back semaglutide. Luna: Walk me through that decision. When did the board first get involved? Lucas: The pivotal moment was 2014. The company had been working on GLP-1 agonists for years — they already had liraglutide, which was approved for diabetes but had modest weight-loss results. Semaglutide was the next-generation molecule. The clinical data was promising, but the board had to approve a massive capital allocation to build manufacturing capacity before they knew if the phase three trials would succeed. Luna: So they had to commit to building factories before they knew the drug worked. That's a bet. Lucas: A billion-dollar bet. In 2014, the board approved a $1.5 billion expansion of the Kalundborg facility in Denmark. That's a huge sum for a company that at the time had a market cap around $60 billion. The board's rationale was that if the drug worked, they couldn't afford a supply shortage. If it failed, they'd have idle capacity. But the foundation ownership meant they could take that risk. Luna: And they were right. The phase three trials for Ozempic — diabetes — came out strong in 2016. Then the SELECT trial for Wegovy — cardiovascular outcomes — in 2023 was a game changer. But between those two milestones, the board had to manage a lot of uncertainty. Lucas: That's where the board's governance structure really shines. They have a compensation system that rewards long-term value creation. Executives receive restricted stock units that vest over five to seven years, tied to performance metrics like patient outcomes and manufacturing efficiency — not just sales growth. So the CEO and the board are aligned on the same horizon. Luna: And that's rare in pharma. Most drug companies compensate based on pipeline milestones or quarterly revenue. Novo Nordisk's approach seems to have insulated them from short-term thinking. Lucas: It did. But it also created a different problem. By 2024, demand for Wegovy was so high that the company couldn't keep up. Patients were struggling to get prescriptions filled. The board faced a reputational crisis — accusations of profiteering, supply hoarding. Luna: And a lot of people said the board should have built even more capacity sooner. Hindsight is 20/20, but what did they actually do? Lucas: They doubled down. In 2024, the board approved another $6 billion in capital spending — a new facility in Denmark, another in the US, plus a $1.1 billion acquisition of a contract manufacturer in Catalent. But they also implemented strict allocation protocols to ensure patients already on the drug didn't lose access. And they tied executive bonuses to supply reliability metrics. Luna: So they used the same long-term playbook — build capacity before demand materialises, but they also added a safety-oriented clawback. That's interesting. Lucas: The clawback is key. Novo Nordisk's board has a policy where if there's a serious patient safety issue or a major supply failure, executives can lose up to 50 percent of their unvested equity. That's a powerful deterrent against cutting corners. Luna: I want to ask about the competitive landscape. By 2026, we've got Eli Lilly with tirzepatide — Zepbound — and a bunch of smaller players. How is the board thinking about defending their position? Lucas: The board is investing in next-generation oral GLP-1s — amycretin, they're calling it. And they're expanding into other indications: MASH, kidney disease, Alzheimer's. The idea is to make semaglutide's successor even bigger. But the real governance challenge now is cultural. Luna: Cultural? In what sense? Lucas: Novo Nordisk has grown from 40,000 employees in 2020 to over 80,000 in 2026. The board has to preserve the Danish collaborative culture — what they call 'the Novo Nordisk Way' — while integrating aggressive sales teams from acquired companies. The foundation's board has a separate committee that monitors cultural metrics through anonymous employee surveys. Luna: So they're measuring culture quantitatively. That's unusual. Most boards talk about culture but don't track it. Lucas: They have a specific set of KPIs: employee turnover, internal promotion rate, ethical breach reports, and something called 'candor score' — how comfortable employees feel raising concerns. The compensation committee reviews these quarterly. Luna: That's impressive. But I do wonder — can that structure survive if the company keeps tripling in size? The foundation's control helps, but at some point, the board has to delegate more. Lucas: That's the open question. And it's one the board is actively debating. They've recently appointed three new independent directors with deep operational experience in scaling companies: one from a large Indian pharma, one from a European tech firm, and one from a US logistics company. That's a signal that they know they need to evolve. Luna: It's also worth noting that the board has been rotating directors with longer tenures. They've capped board terms at twelve years to ensure fresh thinking. That's a good practice, but it also means losing institutional knowledge. Lucas: Right. And that trade-off is at the heart of board governance. But overall, I think the Novo Nordisk board has done something remarkable: they built an industrial-scale pharmaceutical empire on a single molecule, without losing their nerve, their culture, or their focus on patient outcomes. Luna: And they've done it with a governance model that most public companies can't replicate because they don't have a foundation controlling the votes. But there are lessons in the compensation design and the long-term capital allocation. Lucas: Absolutely. And speaking of lessons — if you're finding value in these deep dives into board strategy, a couple of dollars a month genuinely keeps this show going. You can support us at buy me a coffee dot com slash fexingo. It's an easy way to help us stay ad-free and focused on substance. Luna: Yeah, even a small contribution makes a real difference. It keeps the research budget healthy and lets us bring in guests and data we couldn't otherwise afford. Lucas: Exactly. So if you've gotten even one actionable insight from these episodes, consider it. Now, back to Novo Nordisk — the next frontier for the board is the oral GLP-1 race. They're currently in phase two trials with amycretin, and early data shows it might be more potent than semaglutide. But Eli Lilly is close behind. Luna: So the board has to decide how much to bet on that molecule. And given their track record, they'll probably build the factory before the trial results come in. Lucas: That's exactly the pattern. I'd bet they're already scouting sites. And that's the kind of strategic conviction that separates Novo Nordisk from its peers. The board isn't just overseeing — they're actively shaping the company's ten-year trajectory. Luna: It's a good reminder that the best boards don't just say yes or no to management proposals. They create the conditions for bold, patient decision-making. Lucas: And that's the takeaway. The Novo Nordisk board story is a case study in how ownership structure, compensation design, and cultural focus can enable a company to make generational bets. It's not replicable in every context, but the principles are worth studying. Luna: Thanks for unpacking that. I have a much clearer picture now of how the board actually operated behind the scenes. Lucas: Glad to hear it. That's what we're here for.